Day: December 13, 2020
Ghent, 13 December 2020, 5 p.m.Press release / Regulated informationABO-GROUP acquires French engineering firm GEO+ Environnement.ABO-GROUP will acquire all the shares of the French GEO+ Environnement company at the beginning of January 2021. GEO+ Environnement has its head offices in Gardouch, near Toulouse, in the French department of Haute-Garonne, and has four offices in Central, North, East and South-West France.Thanks to around 25 hydrogeologists, ecologists and geologists, the added expertise and knowledge in the mining, quarrying and dyke sectors can thereby also be offered to the other ABO-GROUP home countries.GEO+ Environnement is an independent consultancy specialised in environmental advice in the mineral industry (mines and quarries), with expertise in environment, geology and hydraulic engineering. It is the French reference...
ABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over
Written by Customer Service on . Posted in Public Companies.
Gent, 13 december 2020, 17 uPersbericht / Gereglementeerde informatieABO-GROUP neemt Frans ingenieursbureau GEO+ Environnement over.ABO-GROUP verwerft begin januari 2021 alle aandelen van het Franse GEO+ Environnement. GEO+ Environnement heeft haar hoofdzetel in Gardouch, nabij Toulouse, in het Franse departement Haute-Garonne, met vier kantoren verspreid in het center, het Noorden, Oosten en Zuidwesten van Frankrijk.De toegevoegde expertise en kennis in de sector van mijnbouw, steengroeven en dijken kan dankzij een 25-tal hydrogeologen, ecologen en geologen, hierbij ook in de andere thuislanden van ABO-GROUP aangeboden worden.GEO+ Environnement is een onafhankelijk adviesbureau gespecialiseerd in milieuadvies in de minerale industrie (mijnen en steengroeven), met een expertise in milieu, geologie en waterbouw. Het is hét Frans referentiebureau...
ABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement
Written by Customer Service on . Posted in Public Companies.
Gand, le 13 décembre 2020, 17 heuresCommuniqué de presse / Information réglementéeABO-GROUP acquiert la société française d’ingénierie GEO+ Environnement.ABO-GROUP acquerra la totalité des actions de la société française GEO+ Environnement au début du mois de janvier 2021. GEO+ Environnement a son siège social à Gardouch, près de Toulouse, dans le département français de la Haute-Garonne, avec quatre bureaux dans le centre, le nord, l’est et le sud-ouest de la France.À la clef : une expertise et des connaissances supplémentaires dans le secteur des mines, des carrières et des digues qui pourront désormais être également proposées dans les autres pays d’activité d’ABO-GROUP, grâce à quelque 25 hydrogéologues, écologistes et géologues.GEO+ Environnement est un bureau d’études indépendant spécialisé dans le conseil environnemental...
TCR² Announces RECIST Response in Ovarian Cancer from Ongoing Phase 1/2 Trial of TC-210 in Treatment Refractory Mesothelin-Expressing Solid Tumors
Written by Customer Service on . Posted in Public Companies.
– TC-210 induced tumor regression in all of the first eight patients– Ovarian cancer patient achieved confirmed RECIST partial response (PR)– Overall response rate (ORR) 50% in patients infused with TC-210 and lymphodepletion – Continued manageable toxicity profile – Phase 1 trial amended to accelerate treatment– TCR2 to host conference call Monday, December 14 starting at 8:00am E.T. live webcast availableCAMBRIDGE, Mass., Dec. 13, 2020 (GLOBE NEWSWIRE) — TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced positive interim data from the ongoing Phase 1 portion of the TC-210 ( gavocabtagene autoleucel or “gavo-cel”) Phase 1/2 clinical trial for mesothelin-expressing...
Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 Infected Outpatients with VASCEPA® (Icosapent Ethyl) in Late Breaker Presentation at National Lipid Association (NLA) Scientific Sessions 2020
Written by Customer Service on . Posted in Public Companies.
VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tolerability data using VASCEPA loading doseVASCEPA administration resulted in a significant 52% reduction of the total patient-reported symptom outcome prevalence score as compared to a 24% reduction in the usual care groupLarger follow-on clinical studies have commenced of VASCEPA as a therapeutic option in COVID-19 settings, anticipated to be completed in 2021Amarin to Webcast Discussion of Presented Data on Monday, December 14, 2020 at 8:00 a.m., Eastern Standard TimeDUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 12, 2020 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN)...